SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as President Trump's threats of new tariffs on European nations over Greenland escalate geopolitical tensions, leading to a risk-off market sentiment. The community is divided, with some anticipating a significant market pullback, while others view it as a 'buy the dip' opportunity, also noting a Japan-led bond sell-off as a contributing factor. This environment is fueling discussions about broader market volatility and a flight to safe-haven assets.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following constructive discussions with the FDA regarding a resubmission path for ANKTIVA in bladder cancer, complemented by significant international approvals and strategic partnerships like those recently established in Saudi Arabia for broader cancer indications. This development, coupled with high short interest, is fueling widespread community excitement about a potential paradigm shift in oncology and intense speculation regarding a short squeeze amidst growing calls for expedited access to these innovative treatments.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is actively trending amid escalating US-EU trade tensions driven by President Trump's tariff threats over Greenland, sparking a widespread market sell-off and global risk-off sentiment. The investment community is sharply divided between those anticipating a deeper correction for technology and growth stocks and fervent "buy the dip" proponents. Immediate market focus remains on an upcoming Supreme Court ruling regarding tariff authority and a heavy week of earnings reports, amplifying uncertainty.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is a major talking point following its J.P. Morgan conference appearance, where investors are eagerly seeking clarity on its strategy for advancing the Matrix-M adjuvant technology and securing new collaborations. Community sentiment is sharply focused on management's pace in realizing pipeline potential, including a recent Pfizer agreement and ongoing Sanofi ventures, with an activist investor's growing stake and significant short interest adding to the intense market watch.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is seeing heightened conversation due to recent developments surrounding Trump's assertive stance on Greenland and reactions to a perceived Nobel Peace Prize snub, which has sparked discussions of new tariffs on European nations. The community is actively debating the potential for increased market volatility, geopolitical instability, and the broader economic ramifications of these actions. This ongoing dialogue underscores intense political polarization and its influence on market sentiment.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is generating significant buzz following a substantial upward revision to its future revenue outlook and a surging order backlog, further bolstered by a recent large capital raise. The community is actively discussing its promising potential as a rapidly expanding defense and autonomy platform, especially amidst ongoing negotiations for key acquisitions in the critical drone technology sector.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is trending due to a significant surge in natural gas futures, driven by widespread forecasts for severe arctic cold fronts across the US, intensifying heating demand expectations. The community is actively debating the potential for a powerful short squeeze amidst historically high short interest, while also acknowledging the inherent volatility and decay of leveraged natural gas ETFs like $BOIL, often referred to as a "widow maker". Discussions highlight the impact of this weather event on depleting storage levels, yet some remain cautious, pointing to broader warm winter trends and structural factors like contango, questioning the rally's sustainability.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is actively trending amid recent allegations of money laundering and illicit financial ties, triggering a sharp sell-off across the stock. Despite this, community sentiment is divided, with many dismissing the claims as a coordinated short attack ahead of strong earnings, while others are seizing the opportunity to buy into the fundamentally strong AI-powered ad platform.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending after announcing positive data from its placebo-controlled Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing strong efficacy. The community is actively discussing the oral ITK inhibitor's potential in a large market, with many anticipating significant revaluation and partnership opportunities for its novel mechanism of action.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors react to a significant patent extension for its key products until 2041, coupled with a bullish preliminary business update accelerating IBSRELA's path to $1 billion in revenue by 2029 and multiple analyst price target upgrades. The community is buzzing with renewed acquisition speculation and optimism over the company's long-term value, despite ongoing discussions about short-term price fluctuations attributed to market dynamics. This confluence of positive developments has many viewing Ardelyx as a significantly undervalued biotech with strong commercial execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling...

Lyell Immunopharma (NASDAQ:LYEL) Trading Up 7.3% - What's Next?

Lyell Immunopharma (NASDAQ:LYEL) Shares Up 7.3% - Here's What Happened...

Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4.6% - Here's Why

Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4.6% - Time to Sell...

Lyell Immunopharma (NASDAQ:LYEL) Shares Up 4.2% - Still a Buy?

Lyell Immunopharma (NASDAQ:LYEL) Trading Up 4.2% - Should You Buy...

Lyell Immunopharma (NASDAQ:LYEL) Shares Down 6.7% - Here's Why

Lyell Immunopharma (NASDAQ:LYEL) Trading Down 6.7% - What's Next...

The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar 

Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.

4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow

MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.

Goldman's Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors

Goldman's Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors There are just nine days left in the year, and this year has flown by. We've delivered readers a steady stream of 2026...

Lyell Immunopharma (NASDAQ:LYEL) Shares Up 5.5% - Here's Why

Lyell Immunopharma (NASDAQ:LYEL) Trading Up 5.5% - Here's Why...

Lyell Immunopharma (NASDAQ:LYEL) Reaches New 1-Year High - Time to Buy?

Lyell Immunopharma (NASDAQ:LYEL) Hits New 52-Week High - Here's What Happened...

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

LYEL
Lyell Immunopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LYEL News

LYELLyell Immunopharma Inc